omniture
腾盛博药

Latest News

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high ...

2024-06-07 19:00 2423

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results t...

2024-03-22 19:00 4013

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and roy...

2024-02-14 08:07 4154

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited

2024-01-03 20:00 5168

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...

2023-11-14 06:40 1921

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...

2023-11-14 06:40 1572

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at ...

2023-09-06 18:45 2427

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HB...

2023-08-22 22:00 3343

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to ac...

2023-07-06 07:25 3045

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in ...

2023-07-06 07:19 3015

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to tre...

2023-06-26 07:30 2710

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatm...

2023-06-25 20:00 3584

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potent...

2023-06-01 08:00 2885

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 20...

2023-04-28 09:00 2997

Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepati...

2023-03-24 13:33 3905

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination st...

2022-12-27 20:00 3231

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated ...

2022-10-19 20:00 2139

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable phar...

2022-09-26 20:00 2429
123